

*Evolent	
Clinical guidelines: COLORECTAL CANCER	Original Date: March 2011
Radiation Oncology	Last Revised Date: May 2023
Guideline Number: Evolent_CG_121	Implementation Date: January 2024

GENERAL INFORMATION

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

INDICATIONS FOR RADIATION THERAPY

- **Colon Cancer**
 - Radiation therapy is indicated for T4 tumors with penetration/perforation, intermediate/positive margins, patients with recurrent disease, or for palliative care to relieve symptoms for Stage IV metastatic disease. Radiation therapy should not replace surgical resection
 - 3D Conformal is recommended. 45-50Gy in 25-28 fractions. Boost dose for positive margins an option¹
 - IORT, if available, should be considered for very close or positive margins following resection, particularly for T4 or recurrent cancers, as an additional boost.¹ Where IORT is not available, 10-20Gy external beam radiation and/or brachytherapy to a limited volume can be considered soon after surgery but prior to adjuvant chemotherapy
 - IMRT is not indicated as a standard treatment option and should be reserved for unique situations such as re-irradiation of previously treated patients with recurrence or unique anatomical situations where IMRT facilitates the delivery of recommended target volume doses while respecting accepted normal tissue dose-volume constraints (e.g., coverage of external iliac or inguinal nodes).¹ (Will be reviewed on a case-by-case basis)
 - Proton beam is not an approved treatment option for colorectal cancer.
- **Rectal Cancer**

- Radiation therapy is considered a medically necessary for the following clinical indications: Preoperative or postoperative/adjuvant therapy or as primary therapy if tumor inoperable. Radiation therapy should not replace surgical resection²
 - 3D Conformal Radiation Therapy recommended. 45 -54Gy delivered 25 -30 fractions at 1.8 -2.0Gy per fraction. Boost may be an option. Dosage exceeding 54Gy may be necessary for un-resectable tumors²
 - Short-Course radiation therapy (25Gy in 5 fractions) can also be considered for pre-operative radiation
 - IORT, if available, should be considered for very close or positive margins following resection, particularly for T4 or recurrent cancers, as an additional boost. Where IORT is not available, 10-20Gy external beam radiation and/or brachytherapy to a limited volume can be considered soon after surgery but prior to adjuvant chemotherapy²
 - IMRT is not indicated as a standard treatment option and should be reserved for unique situations such as re-irradiation of previously treated patients with recurrence, or in unique anatomical situations (e.g., coverage of external iliac or inguinal lymph nodes in low-lying rectal tumors).² (Will be reviewed on a case-by-case basis)
 - Proton beam is not an approved treatment option for colorectal cancer.

TREATMENT OPTIONS TO BE REVIEWED ON A CASE-BY-CASE BASIS

Intensity Modulated Radiation Therapy (IMRT)

IMRT is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for colorectal cancer. IMRT may be appropriate for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose heterogeneity is such that unacceptable hot or cold spots are created.

Clinical rationale and documentation for performing IMRT rather than 2D or 3D-CRT treatment planning and delivery will need to:

- Demonstrate how 3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of a patient-specific dose volume histograms and isodose plans.
- Provide tissue constraints for both the target and affected critical structures.

Proton Beam Radiation Therapy

Proton beam is not an approved treatment option for colorectal cancer. There are limited clinical studies comparing proton beam therapy to 3-D conformal radiation. Overall, studies have not shown clinical outcomes to be superior to conventional radiation therapy.

Stereotactic Radiation Therapy

SBRT is not a routine treatment option for Colon cancer but may be considered for patients with oligometastatic disease or for tumors in or near previously irradiated regions.

THE FOLLOWING APPLIES TO CMS (MEDICARE) MEMBERS ONLY

For Proton Beam and Stereotactic Radiotherapy refer to Local Coverage Determination (LCD), if applicable

BACKGROUND

Colorectal cancer, also called colon cancer or large bowel cancer, includes cancerous growths in the colon, rectum and appendix. Cancer of the colon is generally treated with both surgery and chemotherapy. Surgery may be used in the treatment of all stages of rectal cancer. Preoperative radiation therapy and chemotherapy (neoadjuvant therapy) are given to shrink the tumor before surgery, resulting in improved probability for successful resection. Postoperative radiation therapy and chemotherapy (adjuvant therapy) may decrease local recurrence and improve overall survival. It may also be used for palliative treatment to relieve symptoms of metastatic disease. In addition, local recurrences that cause pain, bleeding or other symptoms are appropriately treated with radiation therapy.

REFERENCES

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer Version 2.2022. National Comprehensive Cancer Network (NCCN). Updated October 17, 2022. Accessed December 2, 2022. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Rectal Cancer Version 3.2022. National Comprehensive Cancer Network (NCCN). Updated October 27, 2022. Accessed December 2, 2022. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf

POLICY HISTORY

Date	Summary
May 2023	<ul style="list-style-type: none"> • Removed: IMRT can be approved for low-lying rectal cancers requiring treatment of inguinal lymph nodes. These tumors are often treated like anal cancer. No comparative plan would be necessary. • Added under colon cancer: unique anatomical situations where IMRT facilitates the delivery of recommended target volume doses while respecting accepted normal tissue dose-volume constraints (e.g., coverage of external iliac or inguinal nodes). • Added under colon cancer: Patients with recurrent disease • Added under rectal cancer: (e.g., coverage of external iliac or inguinal lymph nodes in low-lying rectal tumors) • Added under rectal cancer: Short-course radiation therapy (25Gy in fractions) can also be considered for pre-operative radiation • Deleted Additional Resources • Removed “physician review” language
January 2022	<ul style="list-style-type: none"> • Added: IMRT can be approved for low-lying rectal cancers requiring treatment of inguinal lymph nodes. These tumors are often treated like anal cancer. No comparative plan would be necessary.

Reviewed / Approved by Clinical Guideline Committee

Disclaimer: *Evolut Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Evolut uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolut Clinical Guidelines. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolut reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. **Members should contact their Plan customer service representative for specific coverage information.***